CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

durvalumab

Last Updated: November 3, 2020
Result type: Reports
Project Number: PC0234-000
Product Line: Reimbursement Review

Generic Name: durvalumab

Brand Name: Imfinzi

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Extensive-stage small cell lung cancer

Indications: Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Manufacturer Requested Reimbursement Criteria1: As per Health Canada indication: in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Submission Type: Initial

Tumour Type: Lung

Project Status: Pending

Call for patient/clinician input open: November 3, 2020

Call for patient/clinician input closed: December 24, 2020

Anticipated Date: December 1, 2020

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback